Comparison 2. Terbinafine versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical cure	8	1006	Risk Ratio (M‐H, Random, 95% CI)	6.00 [3.96, 9.08]
1.1 Short‐term follow‐up (≤ 52 weeks)	6	800	Risk Ratio (M‐H, Random, 95% CI)	5.60 [3.66, 8.55]
1.2 Long‐term follow‐up (> 52 weeks)	2	206	Risk Ratio (M‐H, Random, 95% CI)	26.01 [3.69, 183.44]
2 Mycological cure	8	1006	Risk Ratio (M‐H, Random, 95% CI)	4.53 [2.47, 8.33]
2.1 Short‐term follow‐up (≤ 52 weeks)	6	800	Risk Ratio (M‐H, Random, 95% CI)	4.60 [2.26, 9.36]
2.2 Long‐term follow‐up (> 52 weeks)	2	206	Risk Ratio (M‐H, Random, 95% CI)	7.79 [0.42, 144.44]
3 Adverse events	4	399	Risk Ratio (M‐H, Random, 95% CI)	1.13 [0.87, 1.47]
4 Recurrence rate	1	35	Risk Ratio (M‐H, Random, 95% CI)	0.05 [0.01, 0.38]